13-11-2024, 22:57

Curium Announces ECLIPSE Trial Has Met Primary Endpoint, Demonstrating a Statistically Significant and Clinically Meaningful Benefit for Patients With PSMA-Positive Metastatic Castration Resistant Prostate Cancer
Globe Newswire13-11-2024, 22:57
1-10-2024, 18:45

Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan
Globe Newswire1-10-2024, 18:45
16-11-2023, 17:14

Curium Announces First Patients in Europe Injected With PYLCLARI® – an Innovative 18F-PSMA Pet Tracer Indicated in Patients With Prostate Cancer
Globe Newswire16-11-2023, 17:14